<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03888183</url>
  </required_header>
  <id_info>
    <org_study_id>201801577A3C601</org_study_id>
    <nct_id>NCT03888183</nct_id>
  </id_info>
  <brief_title>Effect of Preservative-free Low-dose Hyaluronic Acid-containing Salt Solution on Dry Eye Disease</brief_title>
  <official_title>Short-term Supplemental Effect of Preservative-free Low-dose Hyaluronic Acid-containing Salt Solution on Dry Eye Disease - A Randomized, Parallel-group, Double-blind, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a randomized, parallel-group, double-blind, controlled clinical trial to
      evaluate the effect of hyaluronic acid (HA) on dry eye disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a randomized, parallel-group, double-blind, controlled clinical trial to
      compare intervention treatment (Per-Young Eye Drops: preservative-free 0.15% HA) against
      control treatment (AIM Artificial Tears: salt solution without 0.15% HA). All participants
      will be received Per-Young Eye Drops (4 to 8 times per day) or AIM Artificial Tears (4 to 8
      times per day) with 12 weeks. Two drugs are identical in appearance and order of
      administration will be double-blind randomized.

      Primary endpoint:

      To compare the central tear meniscus height (TMHc) of treatment with preservative-free 0.15%
      HA to the treatment with salt solution without 0.15% HA at 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">March 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear meniscus height</measure>
    <time_frame>4 weeks</time_frame>
    <description>To compare the TMHc after blink of treatment with preservative-free 0.15% HA to the treatment with salt solution without 0.15% HA at 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear meniscus height</measure>
    <time_frame>8 weeks and 12 weeks</time_frame>
    <description>To compare the TMHc of treatment with preservative-free 0.15% HA to the treatment with salt solution without 0.15% HA .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface disease index (OSDI) score</measure>
    <time_frame>8 weeks and 12 weeks</time_frame>
    <description>To compare the OSDI score of treatment with preservative-free 0.15% HA to the treatment with salt solution without 0.15% HA. It was ranged from 0-100, in which higher score related to more severe symptom. It was subgroup into normal (0-12), mild (13-22), moderate(23-32), and severe (33-100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Redness score</measure>
    <time_frame>8 weeks and 12 weeks</time_frame>
    <description>To compare the redness score of treatment with preservative-free 0.15% HA to the treatment with salt solution without 0.15% HA. It was obtained by KeratographÂ® 5M, Oculus. The redness score, including total redness score, temporal and nasal bulbar scores, temporal and nasal limbal redness scores, showing the severity of dry eye. The higher redness area imply more severity of dry eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid layer thickness</measure>
    <time_frame>8 weeks and 12 weeks</time_frame>
    <description>To compare the lipid layer thickness of treatment with preservative-free 0.15% HA to the treatment with salt solution without 0.15% HA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear film dynamics</measure>
    <time_frame>8 weeks, 12 weeks</time_frame>
    <description>To compare the tear film dynamics of treatment with preservative-free 0.15% HA to the treatment with salt solution without 0.15% HA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive tear break-up time (NITBUT)</measure>
    <time_frame>8 weeks, 12 weeks</time_frame>
    <description>To compare the NITBUT of treatment with preservative-free 0.15% HA to the treatment with salt solution without 0.15% HA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear fern test</measure>
    <time_frame>8 weeks, 12 weeks</time_frame>
    <description>To compare the tear fern test of treatment with preservative-free 0.15% HA to the treatment with salt solution without 0.15% HA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface staining</measure>
    <time_frame>8 weeks, 12 weeks</time_frame>
    <description>To compare the ocular surface staining of treatment with preservative-free 0.15% HA to the treatment with salt solution without 0.15% HA. The ocular surface staining will be graded according to the Oxford Scheme. Fluorescein stain is applied on the ocular surface, and then corneal and conjunctival staining are evaluated under absorption filters. Staining will be labeled by punctate dots on a series of panels in order of increasing severity and score ranges from 0 to 5 for the treatment eye.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>salt solution without 0.15% HA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>preservative-free 0.15% HA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salt solution without 0.15% HA</intervention_name>
    <description>received AIM Artificial Tears (4 to 8 times per day) with 12 weeks</description>
    <arm_group_label>salt solution without 0.15% HA</arm_group_label>
    <other_name>AIM Artificial Tears</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>preservative-free 0.15% HA</intervention_name>
    <description>received Per-Young Eye Drops (4 to 8 times per day) with 12 weeks</description>
    <arm_group_label>preservative-free 0.15% HA</arm_group_label>
    <other_name>Per-Young Eye Drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged greater than or equal to 20 years (&gt;= 20 years).

          -  The symptom criterium of ocular surface disease index (OSDI) score &gt; 13.

          -  One of the two following examination criteria:

               1. Central tear meniscus height (TMHc) &lt; 0.20 mm,

               2. Noninvasive tear-break time (NITBUT) &lt; 6 s, for at least one eye.

          -  Informed consent form (ICF) signed by the participant or a legal guardian.

        Exclusion Criteria:

          -  Male or female subjects aged less than 20 years (&lt;20 years).

          -  The symptom criterium of ocular surface disease index (OSDI) score &lt; 13.

          -  Central tear meniscus height (TMHc) &gt; 0.20 mm and Noninvasive tear-break time (NITBUT)
             &gt; 6 s for each eye.

          -  Acute inflammatory eye diseases.

          -  Receive ocular or eyelid surgeries before 6 months (except cataract surgery).

          -  Allergy to HA

          -  Pregnancy

          -  Conditions judged by the investigator as unsuitable for this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ing-Chou Lai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ing-Chou Lai, MD</last_name>
    <phone>886-9-75056482</phone>
    <email>lai1@cgmh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming-Tse Kuo, MD, PhD</last_name>
    <phone>886-9-75056495</phone>
    <email>mingtse@cgmh.org.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ing-Chou Lai, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017 Jul;15(3):276-283. doi: 10.1016/j.jtos.2017.05.008. Epub 2017 Jul 20. Review.</citation>
    <PMID>28736335</PMID>
  </reference>
  <reference>
    <citation>Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012 May;31(5):472-8. doi: 10.1097/ICO.0b013e318225415a.</citation>
    <PMID>22378109</PMID>
  </reference>
  <reference>
    <citation>Cho WH, Lai IC, Fang PC, Chien CC, Tseng SL, Lai YH, Huang YT, Kuo MT. Meibomian Gland Performance in Glaucomatous Patients With Long-term Instillation of IOP-lowering Medications. J Glaucoma. 2018 Feb;27(2):176-183. doi: 10.1097/IJG.0000000000000841.</citation>
    <PMID>29240600</PMID>
  </reference>
  <reference>
    <citation>Ho RW, Fang PC, Chao TL, Chien CC, Kuo MT. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm. Sci Rep. 2018 May 30;8(1):8367. doi: 10.1038/s41598-018-26750-5.</citation>
    <PMID>29849166</PMID>
  </reference>
  <reference>
    <citation>Wang CY, Ho RW, Fang PC, Yu HJ, Chien CC, Hsiao CC, Kuo MT. The function and morphology of Meibomian glands in patients with thyroid eye disease: a preliminary study. BMC Ophthalmol. 2018 Apr 12;18(1):90. doi: 10.1186/s12886-018-0763-9.</citation>
    <PMID>29649988</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Ing-Chou Lai, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hyaluronic acid</keyword>
  <keyword>salt solution</keyword>
  <keyword>dry eye disease</keyword>
  <keyword>ocular surface disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

